These findings are somewhat different from a previous study by Xu and colleagues (36), which showed that 4-[3′-(2′′-chlorophenyl)-2′-propen-1′-ylidene]-1-phenyl-3,5-pyrazolidinedione (CPYPP), a small-molecule inhibitor of DOCK2, alleviated the severity of endotoxemia-induced acute lung injury by inhibiting LPS-induced macrophage activation. The gene discussed is DOCK2; the disease is serum lipopolysaccharide activity.